Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome

Detalles Bibliográficos
Autor principal: and Alternative Medicine, Evidence-Based Complementary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Retraction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371514/
https://www.ncbi.nlm.nih.gov/pubmed/37501878
http://dx.doi.org/10.1155/2023/9769353
_version_ 1785078163309592576
author and Alternative Medicine, Evidence-Based Complementary
author_facet and Alternative Medicine, Evidence-Based Complementary
author_sort and Alternative Medicine, Evidence-Based Complementary
collection PubMed
description
format Online
Article
Text
id pubmed-10371514
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-103715142023-07-27 Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and Alternative Medicine, Evidence-Based Complementary Evid Based Complement Alternat Med Retraction Hindawi 2023-07-19 /pmc/articles/PMC10371514/ /pubmed/37501878 http://dx.doi.org/10.1155/2023/9769353 Text en Copyright © 2023 Evidence-Based Complementary and Alternative Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Retraction
and Alternative Medicine, Evidence-Based Complementary
Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_full Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_fullStr Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_full_unstemmed Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_short Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_sort retracted: the value of rivaroxaban combined with ticagrelor in antithrombotic therapy after pci in patients with nonvalvular atrial fibrillation with acute coronary syndrome
topic Retraction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371514/
https://www.ncbi.nlm.nih.gov/pubmed/37501878
http://dx.doi.org/10.1155/2023/9769353
work_keys_str_mv AT andalternativemedicineevidencebasedcomplementary retractedthevalueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome

Ejemplares similares